US 12,171,750 B2
Isoxazoline parasiticide formulations and methods for treating blepharitis
Bobak Robert Azamian, Newport Coast, CA (US); Douglas Michael Ackermann, Reno, NV (US); Shawn D. Hickok, Aliso Viejo, CA (US); and Joseph G. Vehige, Irvine, CA (US)
Assigned to Tarsus Pharmaceuticals, Inc., Irvine, CA (US)
Filed by Tarsus Pharmaceuticals, Inc., Irvine, CA (US)
Filed on May 30, 2023, as Appl. No. 18/325,919.
Application 18/325,919 is a continuation of application No. 17/099,531, filed on Nov. 16, 2020.
Application 17/099,531 is a continuation of application No. 16/221,390, filed on Dec. 14, 2018, granted, now 10,835,517, issued on Nov. 17, 2020.
Claims priority of provisional application 62/746,498, filed on Oct. 16, 2018.
Claims priority of provisional application 62/689,787, filed on Jun. 25, 2018.
Claims priority of provisional application 62/626,612, filed on Feb. 5, 2018.
Claims priority of provisional application 62/615,855, filed on Jan. 10, 2018.
Claims priority of provisional application 62/599,213, filed on Dec. 15, 2017.
Prior Publication US 2023/0293496 A1, Sep. 21, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/422 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 47/26 (2006.01); A61P 27/02 (2006.01); A61P 33/14 (2006.01)
CPC A61K 31/422 (2013.01) [A61K 9/0048 (2013.01); A61K 9/08 (2013.01); A61K 47/26 (2013.01); A61P 27/02 (2018.01); A61P 33/14 (2018.01)] 16 Claims
 
1. A method for treating an ocular Demodex infestation in a human patient in need of treatment thereof, comprising:
topically administering directly to an ocular surface of one or more eyes of the human patient an ophthalmic composition;
wherein the ophthalmic composition comprises:
an effective amount of lotilaner, wherein the lotilaner is present at between about 0.10% and about 0.50% by weight with respect to the total weight of the composition;
a hydrogenated castor oil; and
a polysaccharide thickener.